01167.HK
Jacobio Pharmaceuticals Group Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 6.44
+1.90%Jul 26, 2026, 23:17 UTC
Jacobio Pharma completed the first patient dosing in the Phase IIa clinical trial of its BET inhibitor JAB-8263 for rheumatoid arthritis in China.
Source:Jul 20, 2026, 01:53 UTC
Jacobio Pharma's JAB-23E73 combination therapy for KRAS-mutant pancreatic cancer completed first patient dosing in a Phase Ib/III trial in China.
Source: